Clinical Trial

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 21, 2023 (before its estimated March 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-08-25; most recent amendment 2026-04-24.
Status change: Active, Not Recruiting → Completed 2026-04-24
Status change: Recruiting → Active, Not Recruiting 2023-12-20
Status change: Available → Recruiting 2023-04-03
Trial Details
NCT Number NCT05022901
Lead Sponsor Delcath Systems Inc.
Conditions Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Enrollment 30 participants
Start Date 2022-06-10
Primary Completion 2024-03-01 (estimated)
Study Completion 2024-03-01 (estimated)
Updated on ClinicalTrials.gov 2023-12-21